耐信注意事项

Things to note while taking it:

Carcinoma: There have been no reports of enterochromaffin-like (ECL) cell carcinoid tumors, dysplasia, or tumor formation. 

Clostridium difficile-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase the risk of CDAD (Clostridium difficile-associated diarrhea), particularly in hospitalized patients; patients with persistent diarrhea do not feel improved by a CDAD (Clostridium difficile-associated diarrhea) diagnosis. Use the lowest dose and shortest duration of PPI (proton pump inhibitor) therapy appropriate to treat the disease. 

Cutaneous and systemic lupus erythematosus: New onset or exacerbations of autoimmune diseases have been reported; most cases are cutaneous lupus erythematosus (CLE), most commonly subacute CLE (occurring within weeks to years after continued treatment). Systemic lupus erythematosus (SLE) is less common (usually occurring within days to years after starting treatment) and occurs primarily among young and older adults. If symptoms of CLE or SLE occur, stop treatment and seek evaluation by a specialist; most patients improve within 4 to 12 weeks after stopping treatment. 

Fractures: Treatment with proton pump inhibitors (PPIs) can increase the incidence of osteoporosis-related fractures of the hip, spine, or wrist. Patients receiving high-dose or long-term therapy (≥1 year) should be monitored. Use the lowest effective dose for the shortest time, supplement with vitamin D and calcium, and follow appropriate guidelines to reduce the risk of fractures in high-risk patients. 

Fundic gland polyps: Use of proton pump inhibitors (PPIs) increases the risk of fundic gland polyps, especially in patients with long-term use for more than 1 year. It may be asymptomatic, but nausea, vomiting, or abdominal pain may occur; gastrointestinal bleeding or anemia may occur with ulcerative polyps. A diagnosis of polyps may also increase the risk of small bowel obstruction. Use the lowest dose and shortest duration of PPI (proton pump inhibitor) therapy appropriate to treat the disease. 

Gastrointestinal infections (e.g., Salmonella, Campylobacter): Use of proton pump inhibitors may increase the risk of these infections. 

Hypomagnesemia: Rarely reported, usually with long-term PPI (proton pump inhibitor) use for ≥3 months (most cases >1 year of treatment). It may be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and irregular heartbeats. Consider obtaining serum magnesium concentrations before initiating long-term therapy, especially if digoxin, diuretics, or other drugs known to cause hypomagnesemia are concurrently administered and regularly thereafter. Hypomagnesemia can be corrected with magnesium supplementation and may require discontinuation of esomeprazole. Magnesium levels usually return to normal within 1 week after stopping the medication. 

Interstitial Nephritis: Acute interstitial nephritis has been observed in patients taking PPIs (proton pump inhibitors); it may occur at any time during treatment, usually due to idiopathic hypersensitivity reactions. If acute interstitial nephritis occurs, treatment should be discontinued.

Vitamin B12 Deficiency: Long-term treatment (≥2 years) may result in vitamin B12 malabsorption and subsequent vitamin B12 deficiency. The degree of deficiency is dose-related, with a stronger association in women and younger individuals (under 30 years); the prevalence decreases after discontinuation of treatment.

The above are the precautions provided by our Medical Companion Travel Overseas Medical Consulting Service Company.